Yusimry™
Drug class
- Biologic/biosimilar
- TNF blocker
Generic name
Adalimumab-aqvh
Safety
Efficacy
Convenience
Box warning
Adalimumab can cause serious infections like tuberculosis, sepsis, and fungal infections that may lead to hospitalization or death. It may also raise the risk of cancer, especially lymphoma, in children and teens. Patients should be tested for tuberculosis before starting and be watched carefully during treatment.
Indications
Approved for the treatment of moderate to severe Crohn's disease and inducing/sustaining remission. Approved for the treatment of moderate to severe ulcerative colitis.
How it works
Lowers inflammation (swelling) and quickly brings on remission.
Drug interactions
Do not take adalimumab with another TNF blocker such as etanercept or infliximab.
Pre-treatment screening tests
Viral hepatitis panel, tuberculosis infection test, hepatic panel, complete blood count
Tests during screening
Complete blood count, signs and symptoms of infection, yearly skin exam, yearly hepatic (liver) panel, yearly viral hepatitis panel and tuberculosis infection test.
Payment options
https://patient.yusimry.com/cost-of-yusimryRoute of administration
Frequency
Every 2 weeks
Side effects
Headache, upper respiratory infections (flu or colds), abdominal (stomach) pain, nausea or upset stomach, back pain, and injection site reactions such as pain, redness or swelling.
Contraindications
There are no contraindications listed in the manufacturer's U.S. labeling.
Safety information
Serious infections, allergic reactions, like face swelling, fainting, dizziness, hives, shortness of breath; Nervous system problems; Heart failure; Liver problems; Skin changes that do not heal; Feeling very weak or tired; Burning, numbness, or tingling feeling that is not normal; Change in eyesight; Dizziness; Seizures; Weakness in arms or legs; Any infections that do not heal; Skin lump or growth; Night sweats; Shortness of breath; Changes in eyesight.